)
Edge20 Feb 2026
Dollar General: The Rural Retailer Playbook
How Dollar General built a small-box empire across rural America, scaling value and convenience into one of retail's most durable business models.
Mesoblast
Mesoblast (MSB) investor relations material
Mesoblast H1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2026 earnings summary26 Feb, 2026
Executive summary
Achieved strong growth in Ryoncil/RYONCIL sales following FDA approval and US launch in April 2025, with significant market adoption, onboarding of 49 centers, and broad insurance coverage for over 280 million lives.
Total revenues for H1 FY26 reached $51.3 million, driven by $49 million in Ryoncil/RYONCIL net product revenue.
Net loss for H1 FY26 narrowed to $40.2 million, reflecting higher revenues and increased R&D and SG&A expenses.
Cash reserves stood at $130 million at December 31, 2025, supported by a new $125 million credit facility.
Strategic focus on expanding Ryoncil/RYONCIL indications, advancing pipeline assets (including Revascor and Rexlemestrocel-L), and optimizing manufacturing and commercial partnerships.
Financial highlights
Product revenue for H1 FY26 was $49 million, with total revenues at $51.3 million and gross margin of 93%.
R&D expenses were $46.1–$46.2 million, and SG&A expenses rose to $28.5 million due to commercialization.
Net loss for the period was $40.2 million, improved from $47.9–$48 million in the prior year.
Cash balance at December 31, 2025, was $130 million; operating cash outflow was $30.3 million.
Cost of revenues was $7.6 million, reflecting inventory and amortization costs post-commercialization.
Outlook and guidance
Full-year FY26 Ryoncil/RYONCIL net revenue is projected between $110 million and $120 million.
Operating cash flow usage/net cash spend expected to decline in H2 FY26 due to increased revenues and cost controls.
Targeting 20% pediatric market share for Ryoncil by fiscal year-end, with a long-term goal of 40% peak share.
BLA filing for full approval of Revascor in end-stage HFrEF anticipated next quarter; CLBP Phase 3 trial enrollment to complete by March/April, with data readout and BLA filing targeted for CY27.
Existing cash and Ryoncil sales expected to fund operations for at least the next twelve months; additional capital will be required beyond this period.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Mesoblast
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Mesoblast Limited is an Australian biotechnology company that develops cellular medicines based on mesenchymal lineage cells. The company’s pipeline targets inflammatory and cardiovascular diseases, with therapies in various stages of clinical development. Its operations include research, regulatory affairs, and strategic licensing. Mesoblast Limited is headquartered in Melbourne, Australia, and its shares are listed on the ASX.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage